Totus Medicines is excited to announce that our CEO and co-founder, Neil Dhawan, spokeat the Next-Generation Undruggable Conference in Boston on October 11, 2022. At the conference, Neil discussed the power of Totus' comprehensive high-throughput platform to identify highly specific and potent molecules against previously undruggable targets.
Totus Medicines is a clinical-stage biopharmaceutical company developing novel therapies for cancer and other serious diseases. Our lead product candidate, TTX-33, is a small molecule inhibitor of the TSLP receptor. TSLP is a cytokine that plays a key role in inflammation and immunity. TTX-33 is currently in Phase 2 clinical trials for treating atopic dermatitis, and we are also exploring its potential in other diseases, including psoriasis, Crohn's disease, and ulcerative colitis.
Neil's presentation at the Next-Generation Undruggable Conference focused on how Totus uses its platform to develop new drugs for targets previously impossible to drug. He discussed challenges of identifying new drugs against these targets and the tools and approaches Totus uses to solve these problems.
Totus Medicines is committed to developing innovative medicines that improve patients' lives. We were thrilled to have Neil speak at the Next-Generation Undruggable Conference and to share our vision for a future where all diseases are treatable.
View Press Release